Angela Wardman

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

Yehuda Carmeli, J. Armstrong, Peter J. Laud et al. · The Lancet Infectious Diseases · 2016 · 399 citations

Urinary Tract Infections, Urology, Antimicrobial Susceptibility +11

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

Gregory G. Stone, Paul Newell, Leanne B. Gasink et al. · Journal of Antimicrobial Chemotherapy · 2018 · 77 citations · Full text

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Wright W. Nichols, Gregory G. Stone, Paul Newell et al. · Antimicrobial Agents and Chemotherapy · 2018 · 29 citations · Full text

<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens

Gregory G. Stone, Patricia A. Bradford, Paul Newell et al. · Antimicrobial Agents and Chemotherapy · 2016 · 24 citations · Full text

Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme

Karen Cheng, Paul Newell, Joseph W. Chow et al. · Drug Safety · 2020 · 22 citations · Full text